Last reviewed 2026-04-20 · How we verify

Ebernet (EBERCONAZOLE)

Phase 2 active Small molecule

Ebernet (generic name: EBERCONAZOLE) is a eberconazole drug. It is currently in Phase 2 development.

Eberconazole works by inhibiting the growth of fungi through interference with the fungal cell membrane.

Eberconazole, also known as EBERCONAZOLE, is a small molecule drug in the eberconazole class. It is currently owned by an unknown entity, and its target is not specified. Eberconazole is not FDA-approved for any indications, and its commercial status, patent status, and availability of generic manufacturers are unknown. Further research is needed to determine its safety profile and potential uses. As a result, there is limited information available on this compound.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EBERCONAZOLE
Drug class	eberconazole
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Imagine the fungal cell membrane as a protective shield. Eberconazole disrupts this shield, making it difficult for the fungus to grow and multiply. This ultimately leads to the death of the fungal cells, helping to treat fungal infections.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ebernet CI brief — competitive landscape report
Ebernet updates RSS · CI watch RSS

Frequently asked questions about Ebernet

What is Ebernet?

Ebernet (EBERCONAZOLE) is a eberconazole drug.

How does Ebernet work?

Eberconazole works by inhibiting the growth of fungi through interference with the fungal cell membrane.

What is the generic name of Ebernet?

EBERCONAZOLE is the generic (nonproprietary) name of Ebernet.

What drug class is Ebernet in?

Ebernet belongs to the eberconazole class. See all eberconazole drugs at /class/eberconazole.

What development phase is Ebernet in?

Ebernet is in Phase 2.

Drug class: All eberconazole drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing